ZYME
Zymeworks Inc.25.85
-0.12-0.46%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Q&A boosts ZW251, trispecific prospects
Q&A amplified ZW191's tolerability edge, fueling confidence in ZW251's DAR4 design for fragile HCC patients post-checkpoint therapy, with preclinical PDX responses in 8/10 models and no near-term biomarker mandate. Trispecific T-cell engagers like DLL3 benefit from ZW171 dosing lessons, teasing broader solid/hematologic applications at SITC. H-score granularity showed 191 activity across low/negative FRα expressors, aiding combo potential in earlier lines. Capital plans stay nimble: perpetual buyback authorization, R&D focus, plus royalty portfolio builds from milestones. Jazz ITT queries deflected to partner. ZW251 hits stride.
Key Stats
Market Cap
1.96BP/E (TTM)
-Basic EPS (TTM)
-0.85Dividend Yield
0%Recent Filings
8-K
Annual meeting results approved
Zymeworks held its 2025 annual meeting on December 30, electing Carlos Campoy, Alessandra Cesano, and Robert E. Landry as directors with 80-97% support amid 5-20% withheld votes. Stockholders approved executive pay on an advisory basis (94% for) and ratified KPMG as auditors (99.5% for). Quorum hit 84%. Directors locked in.
8-K
Zymeworks authorizes $125M buyback
Zymeworks launched a strategic shift to royalty-driven growth from Ziihera and licensed assets, authorizing a $125.0 million share repurchase on top of $60.0 million already spent. Scott Platshon resigned from the board November 16 but joined as Acting CIO November 18 to manage cash flows. Cash of $299.4 million as of September 30 funds operations beyond 2028, even post-full buyback.
8-K
Positive Ziihera Phase 3 data
Zymeworks announced positive Phase 3 HERIZON-GEA-01 topline results on November 17, 2025, showing Ziihera plus chemotherapy beat trastuzumab plus chemo on PFS, with a strong OS trend; adding Tevimbra yielded significant OS and PFS gains. Safety matched known profiles, no new signals. Jazz plans sBLA submission in 1H 2026. Milestone potential unlocked.
8-K
Zymeworks Q3 earnings surge
Zymeworks reported Q3 2025 revenue of $27.6 million, up from $16.0 million last year, fueled by a $25.0 million milestone from Johnson & Johnson and $1.0 million in royalties, yet net loss narrowed to $19.6 million from $29.9 million. Encouraging Phase 1 data for ZW191 showed 53% objective response rates, validating their ADC platform, while ZW251 dosing began in hepatocellular carcinoma. Cash stands at $299.4 million, funding operations into 2H-2027. Share repurchases hit $22.7 million, signaling confidence.
10-Q
Q3 FY2025 results
Zymeworks posted Q3 revenue of $27.6M, up 73% y/y from $16.0M, fueled by a $25.0M milestone from J&J on pasritamig's Phase 3 entry and $1.0M in royalties from Jazz and BeOne on Ziihera sales, while YTD revenue soared 128% to $103.5M on milestones from GSK, Daiichi Sankyo, BMS, and BeOne's China approval. Operating loss narrowed to $22.1M from $34.2M y/y, with R&D dipping 2% to $35.6M amid zanidatamab zovodotin discontinuation, though net loss widened slightly to $19.6M from $29.9M due to higher taxes; YTD net loss improved to $39.9M from $99.2M, reconciling with 75.4M diluted shares and $0.53 EPS. Cash and equivalents stood at $64.8M with $234.5M in marketable securities, supporting operations for at least 12 months, while the $60.0M repurchase program advanced with $15.7M spent on 1.0M shares. No non-GAAP metrics disclosed in the 10-Q. Yet competition from biosimilars looms large.
APVO
Aptevo Therapeutics Inc.
1.10+0.06
BCYC
Bicycle Therapeutics plc
7.31-0.02
CGEM
Cullinan Therapeutics, Inc.
10.22-0.60
CUE
Cue Biopharma, Inc.
0.41-0.05
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
HCWB
HCW Biologics Inc.
1.78-0.09
IMTX
Immatics N.V.
10.09+0.11
JAZZ
Jazz Pharmaceuticals plc
169.73+0.20
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
ZLAB
Zai Lab Limited
17.00-0.34